Devices & Diagnostics

Sensus Healthcare files for $23M IPO for non-invasive skin cancer treatments

One of Sensus' essential benefits is that it doesn’t involve cutting, bleeding or stitching, and there is no need for anesthesia, no risk of infection or scarring and no need for reconstructive plastic surgery.

Sensus Healthcare

Sensus Healthcare, a Florida-based biotech developing photon x-ray low energy superficial radiation therapy for non-melanoma skin cancer and keloids, just filed a prospectus for a $23 million initial public offering.

The company is providing a safe and highly effective non-surgical skin cancer treatment that is an alternative to surgery using its SRT-100 technology. With the FDA approved device, low-dose radiation effectively destroys basal cell carcinoma and squamous cell carcinoma, as well as the non-malignant tumor cells that cause keloids.

One of its essential benefits is that it doesn’t involve cutting, bleeding or stitching, and there is no need for anesthesia, no risk of infection or scarring and no need for reconstructive plastic surgery.

Back in October when the company received its 510(k) approval, Sensus’ Chief Technology Officer, Mr. Kal Fishman said in a company statement: “Our systems around the world have treated more patients, more skin cancers, and keloids than any other device. We are dedicated to providing all the tools necessary to achieve maximum results.”

Photo: Screenshot via Sensus Healthcare

Shares0
Shares0